Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.02 on Wednesday. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The firm has a 50 day moving average of $0.04 and a 200 day moving average of $0.04. The stock has a market capitalization of $196,951.30, a price-to-earnings ratio of -0.02 and a beta of 0.74.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.